A recent study from the Case Western Reserve School of Medicine suggests that semaglutide, a medication used for diabetes and weight loss, coudl potentially lower the risk of dementia in individuals with type 2 diabetes (T2D).

Dementia is characterized by a gradual decline in cognitive functions, including memory and clear thinking, resulting from damage to brain cells and impaired connections. Factors such as obesity, T2D, cardiovascular issues, brain injuries, and strokes can contribute to this damage.

The National institutes of Health reports that over 6 million Americans are diagnosed with dementia,leading to more than 100,000 deaths annually. research indicates that addressing modifiable risk factors could prevent up to 45% of dementia cases.

The study, published in the Journal of Alzheimer’s Disease, indicates that T2D patients using semaglutide experienced a substantially lower risk of developing dementia compared to those using other antidiabetic drugs. This effect was notably noticeable in women and older adults.

semaglutide, a glucagon-like peptide receptor (GLP-1R) molecule found in drugs like Wegovy and Ozempic, reduces hunger and regulates blood sugar in T2D patients. it has also demonstrated benefits in reducing cardiovascular diseases.

Led by biomedical informatics professor Rong Xu, the research team analyzed three years of electronic health records from nearly 1.7 million T2D patients across the nation, employing a statistical method that simulates a randomized clinical trial.

The study revealed that patients taking semaglutide had a significantly lower risk of Alzheimer’s disease-related dementia compared to those taking other anti-diabetic medications, including other GLP-1R-targeting drugs.

Semaglutide’s Potential Impact

“There is no cure or effective treatment for dementia, so this new study provides real-world evidence for it’s potential impact on preventing or slowing dementia development among at-high risk population,” said Xu, who also directs the School of Medicine’s Center for AI in Drug Revelation and is a member of the cancer Genomics Epigenomics Program at the Case Extensive Cancer Center.

“Our results indicate that research into semaglutide’s use for dementia prevention will need to be further investigated through randomized clinical trials.”

While the findings suggest semaglutide’s potential in preventing dementia, the researchers acknowledge that the study’s limitations prevent definitive causal conclusions.